[1] |
ALIBERTI S, DELA CRUZ C S, AMATI F, et al. Community-acquired pneumonia[J]. Lancet, 2021, 398(10303):906-919.
DOI
PMID
|
[2] |
VAUGHN V M, DICKSON R P, HOROWITZ J K, et al. Community-acquired pneumonia:a review[J]. JAMA, 2024, 332(15):1282-1295.
|
[3] |
EWIG S, BIRKNER N, STRAUSS R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality[J]. Thorax, 2009, 64(12):1062-1069.
DOI
PMID
|
[4] |
CHALMERS J D, SINGANAYAGAM A, AKRAM A R, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis[J]. Thorax, 2010, 65(10):878-883.
DOI
PMID
|
[5] |
ZHU F M, XU J, HE Q Y, et al. Association of serum interleukin-2 with severity and prognosis in hospitalized patients with community-acquired pneumonia:a prospective cohort study[J]. Intern Emerg Med, 2024, 19(7):1929-1939.
|
[6] |
WEN X, LENG P, WANG J, et al. Clinlabomics:leveraging clinical laboratory data by data mining strategies[J]. BMC Bioinformatics, 2022, 23(1):387.
|
[7] |
ELLIS H L, WAN B, YEUNG M, et al. Complementing chronic frailty assessment at hospital admission with an electronic frailty index(FI-Laboratory)comprising routine blood test results[J]. CMAJ, 2020, 192(1):E3-E8.
|
[8] |
OSMAN A D, HOWELL J, YEOH M, et al. Benefits of emergency department routine blood test performance on patients whose allocated triage category is not time critical:a retrospective study[J]. BMC Health Serv Res, 2024, 24(1):1252.
|
[9] |
METLAY J P, WATERER G W, LONG A C, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America[J]. Am J Respir Crit Care Med, 2019, 200(7):e45-e67.
|
[10] |
TOGUN T, HOGGART C J, AGBLA S C, et al. A three-marker protein biosignature distinguishes tuberculosis from other respiratory diseases in Gambian children[J]. EBioMedicine, 2020,58:102909.
|
[11] |
WANG X, JIAO J, WEI R, et al. A new method to predict hospital mortality in severe community acquired pneumonia[J]. Eur J Intern Med, 2017,40:56-63.
|
[12] |
LIU J X, BAI J S, ZHANG Q, et al. A new prediction model for prolonged hospitalization in adult community-acquired pneumonia(CAP)patients[J]. Clin Lab, 2022, 68(11):2271-2277.
|
[13] |
ZHENG X, HUANG Z, WANG D, et al. A new haematological model for the diagnosis and prognosis of severe community-acquired pneumonia:a single-center retrospective study[J]. Ann Transl Med, 2022, 10(16):881.
|
[14] |
曾瑞璜, 王小林, 曾叶, 等. 基于数据挖掘模型分析CA125、NLR、PLR、hs-CRP联合检测对社区获得性肺炎伴胸腔积液的临床意义[J]. 检验医学, 2020, 35(11):1103-1107.
DOI
|
[15] |
WITTERMANS E, VAN DE GARDE E M, VOORN G P, et al. Neutrophil count,lymphocyte count and neutrophil-to-lymphocyte ratio in relation to response to adjunctive dexamethasone treatment in community-acquired pneumonia[J]. Eur J Intern Med, 2022,96:102-108.
|
[16] |
孙康德, 虞中敏, 严育忠. 不同感染指标在细菌性血流感染早期诊断和预后评估中的价值[J]. 检验医学, 2024, 39(3):222-226.
DOI
|
[17] |
朱红, 朱宇清, 顾国宝. 正五聚体蛋白3在社区获得性肺炎临床诊断中的意义[J]. 检验医学, 2020, 35(5):424-427.
DOI
|
[18] |
李晓烂, 何永鸿, 邓俊, 等. PCT、NLR、CAR对社区获得性重症肺炎患者短期预后的预测价值[J]. 重庆医学, 2025, 54(1):86-90.
|